Nasdaq · CIK 0001799448
ALGS Aligos Therapeutics, Inc.
Insider trading from SEC Form 4. Last filing Jun 29, 2026.
Aligos Therapeutics, Inc. (ALGS) has 22 SEC Form 4 filings on file from 10 insiders, the latest filed on Jun 29, 2026. No insider bought or sold on the open market in the last 90 days; rows filed in that time are grants, exercises, tax withholding and other transactions that carry no view on the price.
Last 90 days
Signals
Open-market buys and sells at Aligos Therapeutics, Inc., scored.
Transactions
Every row filed, 22 in all.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jun 25, 2026 | Carole Nuechterlein director | AGrant or award Stock Option (Right to Buy)derivative | +5,860 | $0.00 | $0 | 5,860 | Jun 29, 2026 |
| Jun 25, 2026 | James Paul Scopa director | AGrant or award Stock Option (Right to Buy)derivative | +5,860 | $0.00 | $0 | 5,860 | Jun 29, 2026 |
| Jun 25, 2026 | Bridget A Martell director | AGrant or award Stock Option (Right to Buy)derivative | +5,860 | $0.00 | $0 | 5,860 | Jun 29, 2026 |
| Jun 25, 2026 | Margarita Chavez director | AGrant or award Stock Option (Right to Buy)derivative | +5,860 | $0.00 | $0 | 5,860 | Jun 29, 2026 |
| Jun 25, 2026 | Heather Preston director | AGrant or award Stock Option (Right to Buy)derivative | +5,860 | $0.00 | $0 | 5,860 | Jun 29, 2026 |
| Jun 25, 2026 | Peter Hirth director | AGrant or award Stock Option (Right to Buy)derivative | +5,860 | $0.00 | $0 | 5,860 | Jun 29, 2026 |
| Mar 9, 2026 | Lawrence Blatt President and CEO | AGrant or award Stock Option (Right to Buy)derivative | +105,840 | $0.00 | $0 | 105,840 | Mar 11, 2026 |
| Mar 9, 2026 | Lesley Ann Calhoun See Remarks | AGrant or award Stock Option (Right to Buy)derivative | +37,485 | $0.00 | $0 | 37,485 | Mar 11, 2026 |
| Mar 9, 2026 | Nikhil Aneja Principal Accounting Officer | AGrant or award Stock Option (Right to Buy)derivative | +9,450 | $0.00 | $0 | 9,450 | Mar 11, 2026 |
| Mar 9, 2026 | Julian A. Symons See Remarks | AGrant or award Stock Option (Right to Buy)derivative | +23,310 | $0.00 | $0 | 23,310 | Mar 11, 2026 |
| Jul 16, 2025 | Julian A. Symons See Remarks | AGrant or award Stock Option (Right to Buy)derivative | +16,000 | $0.00 | $0 | 16,000 | Jul 18, 2025 |
| Jul 16, 2025 | Lawrence Blatt President and CEO | AGrant or award Stock Option (Right to Buy)derivative | +179,800 | $0.00 | $0 | 179,800 | Jul 18, 2025 |
| Jul 16, 2025 | Lesley Ann Calhoun See Remarks | AGrant or award Stock Option (Right to Buy)derivative | +40,185 | $0.00 | $0 | 40,185 | Jul 18, 2025 |
| Jun 25, 2025 | Bridget A Martell director | AGrant or award Stock Option (Right to Buy)derivative | +5,860 | $0.00 | $0 | 5,860 | Jun 26, 2025 |
| Jun 25, 2025 | Margarita Chavez director | AGrant or award Stock Option (Right to Buy)derivative | +5,860 | $0.00 | $0 | 5,860 | Jun 26, 2025 |
| Jun 25, 2025 | Heather Preston director | AGrant or award Stock Option (Right to Buy)derivative | +5,860 | $0.00 | $0 | 5,860 | Jun 26, 2025 |
| Jun 25, 2025 | Peter Hirth director | AGrant or award Stock Option (Right to Buy)derivative | +5,860 | $0.00 | $0 | 5,860 | Jun 26, 2025 |
| Jun 25, 2025 | James Paul Scopa director | AGrant or award Stock Option (Right to Buy)derivative | +5,860 | $0.00 | $0 | 5,860 | Jun 26, 2025 |
| Jun 25, 2025 | Carole Nuechterlein director | AGrant or award Stock Option (Right to Buy)derivative | +5,860 | $0.00 | $0 | 5,860 | Jun 26, 2025 |
| Feb 28, 2025 | Lesley Ann Calhoun See Remarks | AGrant or award Stock Option (Right to Buy)derivative | +47,271 | $0.00 | $0 | 47,271 | Mar 4, 2025 |
| Feb 28, 2025 | Julian A. Symons See Remarks | AGrant or award Stock Option (Right to Buy)derivative | +21,693 | $0.00 | $0 | 21,693 | Mar 4, 2025 |
| Feb 28, 2025 | Lawrence Blatt President and CEO | AGrant or award Stock Option (Right to Buy)derivative | +140,103 | $0.00 | $0 | 140,103 | Mar 4, 2025 |
Insiders
Everyone who has filed a Form 4 here.
- Nikhil AnejaPrincipal Accounting Officer
- Lawrence BlattPresident and CEO
- Lesley Ann CalhounSee Remarks
- Margarita Chavezdirector
- Peter Hirthdirector
- Bridget A Martelldirector
- Carole Nuechterleindirector
- Heather Prestondirector
- James Paul Scopadirector
- Julian A. SymonsSee Remarks
Questions about ALGS
Answered from the filings on this page, as of the latest one.
Are insiders buying ALGS?
No. In the last 90 days no insider at Aligos Therapeutics, Inc. bought or sold shares on the open market according to SEC Form 4 filings. The rows on file from that period are grants, exercises, tax withholding or other transactions, which carry no view on the price.
Who was the last insider to trade ALGS on the open market?
No open-market trade has been scored at Aligos Therapeutics, Inc.. The latest Form 4 on file was filed on Jun 29, 2026 and holds grants, exercises or other rows that are not market trades.
How many insiders file Form 4 at Aligos Therapeutics, Inc.?
10 people have filed a Form 4 at Aligos Therapeutics, Inc., among them Nikhil Aneja (Principal Accounting Officer), Lawrence Blatt (President and CEO), Lesley Ann Calhoun (See Remarks). Officers, directors and holders of more than 10% of a share class must report their trades within two business days.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.